Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 12/20 | 0.39 |
| ▸ | HRH1 | P35367 | 12/20 | 0.39 |
| ▸ | GPR183 | P32249 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14607694 | 0.96 | HRH2 (0.41) | HRH2HRH1USP2 | |
| SCHEMBL14573940 | 0.88 | HRH2 (0.33) | HRH2HRH1THRBALDH1A1 | |
| SCHEMBL14573947 | 0.85 | THRB (0.33) | THRBALDH1A1 | |
| SCHEMBL5154021 | 0.85 | THRB (0.33) | HRH2HRH1THRBALDH1A1 | |
| SCHEMBL5151405 | 0.82 | ALDH1A1 (0.34) | THRBALDH1A1 | |
| SCHEMBL5148701 | 0.77 | HRH2 (0.36) | HRH2HRH1 | |
| SCHEMBL14607630 | 0.74 | GNAI3 (0.38) | HRH2HRH1USP2ALDH1A1LMNA | |
| SCHEMBL5150806 | 0.73 | MEN1 (0.33) | HRH2HRH1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5155296 | 0.73 | MEN1 (0.33) | HRH2HRH1ALDH1A1 | |
| SCHEMBL1048005 | 0.69 | GPR183 (0.47) | HRH2HRH1GPR183USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | GLS, NOS2, NOS1 | HRH2 2566/4885HRH1 3401/4885GPR183 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.